The Rivkin Center is proud to announce that we have awarded $540,000 in ovarian cancer research grants to six scientists from the US and abroad. While the pandemic continues to create challenges for small nonprofits, the Rivkin Center is thankful to our community of supporters who give us the ability to fund critical, life-saving research. To date, the Rivkin Center has funded $15.8 million in ovarian cancer research grants.
Despite being the deadliest gynecological cancer, ovarian cancer continues to be underfunded by federal funding agencies when compared to other cancers. The Rivkin Center’s unique seed funding approach provides ovarian cancer researchers leverage to access larger federal funding sources and make a major impact on moving ovarian cancer research forward. Our Awardees are highly successful at receiving these additional funds to further their life-saving work in ovarian cancer. For every dollar the Rivkin Center invests in research, Rivkin Awardees bring in an additional $15 in outside funding within 5 years or less of their Rivkin Award.
Our 2022 Awardees are leading high-impact research projects focused on overcoming resistance to therapy, discovering biomarkers for early detection, improving the effectiveness of immunotherapies, and improving the quality of life for ovarian cancer survivors. The funded studies include four Pilot Study Awards, which provide funding for novel ideas and innovative approaches to research questions that venture out of the scientific mainstream (More info on funded Pilot Studies). We also funded two Scientific Scholar Awards, which are designed to attract new investigators to ovarian cancer research and support the novel ideas they bring to the table (More info on funded Scientific Scholars).
The mission of the Rivkin Center is to improve the health of people with ovaries by helping them prevent, detect early, and survive ovarian and breast cancer. We do this by investing in cutting-edge ovarian cancer research, educating people on how to prevent and detect ovarian and breast cancer as early as possible, and fostering an ever-growing community of survivors, patients, researchers, clinicians, advocates, and supporters. Learn more at www.rivkin.org.